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A Non-Stop S-Antigen Gene Mutation Is Associated With Late Onset Hereditary
Retinal Degeneration in Dogs
Abstract
Purpose
Purpose: To identify the causative mutation of canine progressive retinal atrophy (PRA) segregating as an
adult onset autosomal recessive disorder in the Basenji breed of dog.
Methods
Methods: Basenji dogs were ascertained for the PRA phenotype by clinical ophthalmoscopic
examination. Blood samples from six affected cases and three nonaffected controls were collected, and
DNA extraction was used for a genome-wide association study using the canine HD Illumina single
nucleotide polymorphism (SNP) array and PLINK. Positional candidate genes identified within the peak
association signal region were evaluated.
Results
Results: The highest -Log10(P) value of 4.65 was obtained for 12 single nucleotide polymorphisms on
three chromosomes. Homozygosity and linkage disequilibrium analyses favored one chromosome,
CFA25, and screening of the S-antigen (SAG) gene identified a non-stop mutation (c.1216T>C), which
would result in the addition of 25 amino acids (p.*405Rext*25).
Conclusions
Conclusions: Identification of this non-stop SAG mutation in dogs affected with retinal degeneration
establishes this canine disease as orthologous to Oguchi disease and SAG-associated retinitis
pigmentosa in humans, and offers opportunities for genetic therapeutic intervention.
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A non-stop S-antigen gene mutation is associated with late onset
hereditary retinal degeneration in dogs
Orly Goldstein,1 Julie Ann Jordan,1 Gustavo D. Aguirre,2 Gregory M. Acland1
Baker Institute for Animal Health, Cornell University College of Veterinary Medicine, Ithaca, NY; 2School of Veterinary
Medicine, University of Pennsylvania, Philadelphia, PA
1

Purpose: To identify the causative mutation of canine progressive retinal atrophy (PRA) segregating as an adult onset
autosomal recessive disorder in the Basenji breed of dog.
Methods: Basenji dogs were ascertained for the PRA phenotype by clinical ophthalmoscopic examination. Blood
samples from six affected cases and three nonaffected controls were collected, and DNA extraction was used for a
genome-wide association study using the canine HD Illumina single nucleotide polymorphism (SNP) array and PLINK.
Positional candidate genes identified within the peak association signal region were evaluated.
Results: The highest -Log10(P) value of 4.65 was obtained for 12 single nucleotide polymorphisms on three chromosomes. Homozygosity and linkage disequilibrium analyses favored one chromosome, CFA25, and screening of the
S-antigen (SAG) gene identified a non-stop mutation (c.1216T>C), which would result in the addition of 25 amino acids
(p.*405Rext*25).
Conclusions: Identification of this non-stop SAG mutation in dogs affected with retinal degeneration establishes this
canine disease as orthologous to Oguchi disease and SAG-associated retinitis pigmentosa in humans, and offers opportunities for genetic therapeutic intervention.

The gene S-antigen (SAG), also known as arrestin,
encodes a major soluble rod outer segment protein that exemplifies a family of inhibitory proteins that bind tyrosine-phosphorylated receptors to block their interaction with specific
G-proteins to terminate a signal chain. In the retina, arrestin
binds to activated rhodopsin [1] in rod outer segments, to
hinder G-protein binding and quench rhodopsin activity [2,3].
Mutations in this gene in humans have been associated with
Oguchi disease, a rare form of autosomal recessive stationary
night blindness (HGMD). This disease has an unusual but
characteristic clinical feature, the Mizuo-Nakamura phenomenon, in which an unusual golden-yellow discoloration of the
fundus disappears in the dark-adapted condition and reappears shortly after exposure to light [4]. Patients with Oguchi
disease usually have night blindness but normal color vision
and normal cone function [5,6]. Patients exhibiting Oguchi
disease may later develop retinitis pigmentosa (RP), and in
other cases, the presence of RP can mask signs of Oguchi
disease [7-12].
Progressive retinal atrophy (PRA) comprises a group
of genetically inherited diseases affecting dogs of various
breeds. Similar to RP in humans, PRA is characterized by
photoreceptor degeneration causing progressive vision loss,
Correspondence to: Orly Goldstein, Baker Institute for Animal
Health, Cornell University College of Veterinary Medicine, Ithaca,
NY 14853; Phone: (607) 256-5691; FAX: (607) 256-5608; email:
og26@cornell.edu

culminating in blindness. This is a highly heterogeneous
group of diseases with more than 12 different causative
gene mutations already identified in canine populations,
causing either early or late onset disease, and inherited as
autosomal dominant, autosomal recessive, or X-linked [for a
review, see 13]. These canine mutations result in phenotypes
resembling orthologous human diseases and provide valuable
large animal models for studying the molecular basis of the
diseases, and for preclinical trials of potential therapies.
In the Basenji breed, the adult onset of PRA was
observed, with initial visual loss in dim light (night blindness), which gradually progressed to total blindness. Initial
visual loss affects the peripheral visual field, but unless the
dog is used for high visual performance tasks such as agility
work, the reduction in the visual field (tunnel vision) may not
be apparent. Despite tunnel vision and night blindness, many
Basenjis affected with PRA retain adequate forward daylight
vision for many years, sometimes for their entire natural
life. This phenotype highly resembles progressive rod-cone
degeneration (prcd), late onset retinal degeneration affecting
multiple breeds caused by a point mutation in the PRCD gene
[14]. A complementary breeding test for dogs affected with
prcd excluded allelism between these two similar diseases
[15], and this has been confirmed with PRCD genotyping.
Complicating this broadly recognizable clinical phenotype
has been considerable heterogeneity in the disease manifestation, and uncertainty about whether this clinical heterogeneity
represented a single protean disorder or an underlying genetic
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heterogeneity. This problem has been further complicated by
the extremely small gene pool of Basenjis in the American
breeding population and the multiple inbreeding loops
apparent in pedigree analysis.
Linkage disequilibrium (LD) enables genome-wide
association mapping in populations even when the extended
pedigree information normally required for linkage analysis
is either incomplete or missing entirely. Furthermore, the
development of genome-wide single nucleotide polymorphism
(SNP) chip arrays has made such mapping widely available
for humans and several other species, including the dog. In
humans, mapping has been particularly successful in isolated
populations [16-20]. In the broader canine population, each
breed comprises such a genetically isolated population, with
extensive LD blocks, making the association approach attractive for mapping traits and disease-causative genes [21-25].
In this study, we report a genome-wide association
study (GWAS) to map a specific form of PRA in the Basenji
breed of dog, using six affected dogs and three control dogs.
Together with homozygosity analysis and consideration of
the mode of inheritance, we identified a non-stop mutation
in SAG that cosegregated with the disease phenotype and
caused the disease. This creates an opportunity to study
the molecular basis of SAG-associated retinal diseases, and
a model for evaluating potential therapeutic approaches for
Oguchi disease and SAG-associated RP in humans.
METHODS
Samples: All procedures involving animals were conducted
following the guidelines of the Institute for Laboratory
Animal Research (Guide for the Care and Use of Laboratory Animals), the U.S. Public Health Service (Public Health
Service Policy on Humane Care and Use of Laboratory
Animals), and the Association for Research in Vision and
Ophthalmology (ARVO) Statement for the Use of Animals
in Ophthalmic and Vision Research. Blood samples were
collected by cephalic or jugular venepuncture into vacutainer
tubes containing ethylenediaminetetraacetic acid (EDTA)
anticoagulant from 80 purebred Basenji dogs: 19 diagnosed
clinically as affected with PRA, six diagnosed clinically as
tentatively affected with PRA, 18 nonaffected controls beyond
the assumed age of risk (at least 6 years of age), and 37 with
no assigned phenotype either because they were younger than
the assumed age of risk or due to lack of information. Blood
was stored at 4 °C or -20 °C until DNA extraction. DNA was
similarly extracted from blood samples of 110 purebred dogs
from 22 different breeds not known to segregate this disease
(Appendix 1).
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Phenotypic evaluation of study dogs: Ascertainment of
disease phenotype was based entirely on indirect ophthalmoscopic examination by board-certified veterinary ophthalmologists. In the minority of cases, the ophthalmoscopic
diagnosis was confirmed with clinical electroretinography.
The cases studied in the present report include only dogs
examined and diagnosed by either or both of two of the
authors (GMA, GDA), although in several cases the initial
diagnostic examination was previously performed by other
veterinarians.
Genome-wide association study: Of the 19 purebred Basenji
dogs diagnosed clinically as affected with PRA, six were
selected as cases for association analysis, based on confidence in the disease ascertainment (dogs affected with stage
II PRA), consistency of the disease phenotype among the
selected dogs, pedigree information supporting autosomal
recessive inheritance identical by descent (IBD), and choosing
the least closely related set of dogs affected with PRA available (four dogs had no parents or grandparents in common).
Among 43 Basenji dogs not expressing PRA symptoms,
three dogs not affected with PRA were selected for the control
group based on having no parents or grandparents in common
with each other, being clinically diagnosed as nonaffected
with PRA at an age beyond the apparent age of risk for onset
of the disease (ages 11.7, 7.5, and 6 years old), being free of
other ocular abnormalities that might obscure or confuse the
presence of PRA, and being close relatives of the affected
dogs chosen as cases. The unaffected dog at age 6, although
borderline for the age of onset, was a sibling of an affected
dog, and was chosen to accomplish the fourth criterion.
Samples were genotyped using the Illumina Canine SNP
chip (HD Canine SNP Chip), which comprises 173,662 SNP
loci, following the manufacturer’s standard protocol. Genotypes were called using GenomeStudio (Illumina, San Diego,
CA). Genotype calls were converted into Plink-format files,
and association was tested using the association command
without pedigree or sex information (PLINK) [26]. The
genotype calls for chromosomes 4, 13, and 25 were retrieved
from the files and assembled into haplotypes to identify
homozygous blocks.
Homozygous block analysis: Homozygous block analysis
was performed on affected dogs only (n=6) using Plink,
under the following criteria: sliding window criteria: 1,000
Kb, 150 SNPs, five missing calls, one heterozygous call,
0.05 threshold; homozygous segment criteria: length 1,000
Kb, 150 SNPs, 50 density (Kb/SNP). The output was then
filtered for those chromosomes where all six cases showed
a minimum of one homozygous segment anywhere in the
chromosome. The segments then were aligned within each
1872
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chromosome, to identify those where all six dogs shared the
same homozygous block. For all such regions, genotype calls
were retrieved to determine whether all homozygous blocks
were homozygous for the same haplotype. If so, then the
“affected haplotype” was compared to haplotypes observed
in the control group.
Candidate gene analysis: Within a homozygous block on
chromosome 25 (CFA25), two genes were considered candidates: S-antigen, arrestin (SAG), which has been associated
with Oguchi disease, as well as retinitis pigmentosa [27-29],
and potassium inwardly-rectifying channel, subfamily
J, member 13 (KCNJ13), which has been associated with
snowflake vitreoretinal degeneration and Leber congenital
amaurosis [30,31].
SAG screening was performed on five dogs: one Basenji
affected with PRA and its nonaffected litter-mate, two nonaffected Basenji dogs, and one normal Boxer dog. Eighteen
primer pairs were used to amplify the 16 coding exons,
as well as two intronic regions rich with single nucleotide
polymorphisms (Appendix 2: A). KCNJ13 gene screening
was conducted on six dogs: two affected Basenji dogs, three
unaffected Basenjis, and one normal Boxer dog. Nine primer
pairs were designed to amplify the three exons of the gene
(Appendix 2B). PCR products of both genes were sequenced,
and sequences aligned using Sequencher 4.2.2 Software
(Gene Codes, Ann Arbor, MI).
S-antigen mutation screening in the Basenji population and
in other breeds: The identified SAG non-stop mutation was
genotyped on the complete set of Basenji dogs available
(N=80) with PCR using primer pairs flanking the mutation
(Appendix 2A, pair number 18), followed by sequencing. An
allele-specific extension test was then designed to screen
110 dogs from 22 breeds (Appendix 1). One primer pair,
containing a forward primer specific to the wild-type allele,
amplifies a 259 bp fragment, and a separate primer pair,
containing a forward primer specific to the mutant allele,
amplifies a 531 bp product (Appendix 2C). Both forward
primers contain a mismatch in the 3′ penultimate base.
RESULTS
Clinical evaluation: PRA as a clinical disease in the Basenji
was, in broad terms, typical adult onset canine retinal degeneration. The first ophthalmoscopically observed evidence
of disease was irregular hypo- and hyperreflectivity of the
tapetal fundus. This phenomenon, taken as evidence of
retinal thinning, is referred to as stage I or early stage PRA.
Basenjis affected with PRA typically exhibited evidence of
stage I PRA at about 5 years of age. These dogs when reexamined ophthalmoscopically at a later age typically showed
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progression of disease by thinning (attenuation) of the retinal
vasculature, which usually became ophthalmoscopically
evident by 6 or 7 years of age. This phenomenon, taken as
evidence of reduced blood flow through the retinal vasculature, is referred to as stage II or mid-stage PRA. In all of these
respects, Basenjis affected by PRA closely resemble dogs of
other breeds affected by the prcd form of PRA.
Clinical diagnosis of PRA in the Basenji was complicated
by several factors, however. These included a common prevalence of conus in dogs affected with PRA and nonaffected
dogs. Conus refers to a roughly triangular region immediately superior to the optic nerve head in which the tapetum
is yellow (and may be hyperreflective) compared to the
surrounding green tapetal region. This phenomenon is seen,
though less frequently, in normal dogs of other breeds, but
also is seen in dogs of other breeds as one of the earliest signs
of retinal thinning. In the fundus of Basenjis affected with
PRA, this area of conus is sometimes observed to expand and
become hyperreflective. Second, the optic nerve head is typically less myelinated and thus less extensive over the fundus
than is typical of other breeds of dog. Also seen repeatedly
in Basenjis affected with PRA and nonaffected Basenjis was
a strange mottled golden-yellow-brown discoloration of the
tapetal fundus that obscured the tapetal reflection in a patchy
manner, and gave the fundus a beaten bronze appearance.
This fundus change, termed bronzing, could either mask
the earliest signs of retinal degeneration in some Basenjis
affected with PRA or produce a mottled variation in tapetal
reflectivity that to some extent mimicked the earliest signs of
retinal degeneration in Basenjis that eventually proved to be
not affected with PRA.
Finally, the fundus appearance in Basenjis affected with
PRA was often patchy, or non-uniform, within a given eye,
between the two eyes of a given affected dog, and among
affected dogs. To some extent, this fundus appearance is
observed in other forms of canine PRA, but was particularly
evident in the eyes of Basenjis affected with PRA (Figure 1).
Pedigree analysis and selection of cases and controls: The
breeding population of Basenjis in the United States of
America (i.e., Basenjis registered with the American Kennel
Club) descends from a small number of founders, and has
a complicated pedigree structure with multiple inbreeding
loops and overlapping generations. In combination with
the late age of onset, and the heterogeneous clinical nature
of the disease, this made pedigree analysis more uncertain than usual in terms of establishing the likely mode of
inheritance. A subset of six affected dogs were thus chosen
for the genome-wide association study with criteria (see the
Methods) intended to maximize the likelihood that all six
1873
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Figure 1. Fundus photographs of a nine-year-old Basenji dog affected with progressive retinal atrophy (PRA; Dog 6, Figure 2). A: Fundus
photographs of the right eye were assembled into a montage. B: Fundus photographs of the left eye were assembled into a montage. Retinal
degeneration is evidenced by the thin retinal blood vessels (red arrows), pallid optic nerve head (white arrows), and an irregular pattern of
tapetal reflectivity (yellow arrows). The yellow region immediately superior to the optic nerve head in both eyes (blue arrows) is an expanded
area of conus (see text).

dogs were affected with a single autosomal recessive disease
inherited from a common ancestor, and thus identical by
descent (Figure 2).
Genome-wide association study results: Nine dogs were
genotyped for the 173,662 SNPs on the HD Canine Illumina
array: six affected with PRA and three controls. Genotype
calls were converted to Plink files, and association analysis
was run comparing the six affected dogs to the three controls,
without considering pedigree relationship or gender. The
highest -Log10(P) value of 4.65 was obtained for 12 SNPs:
one SNP on CFA4, seven on CFA13, and four SNPs on
CFA25 (Table 1; Figure 3). All affected dogs were homozygous for the same allele of the single CFA4 SNP (at position
14,140,022), and all non-affected dogs were homozygous
for the complementary allele. Haplotype analysis in a 2 Mb
interval surrounding this SNP (13,146,696–15,141,399), identified a 1.05Mb block of homozygosity in the control group
(13,378,063–14,426,721), and heterozygosity in five out of the
six affected dogs (data not shown). Since the cross-breeding
test with dogs affected with PRCD suggested that the disease
is recessive [15], this locus was not further investigated.
Affected dogs were all homozygous for one allele at all
seven SNPs on CFA13, and nonaffected dogs were homozygous for the complementary allele. Haplotype analysis of
the approximately 7 Mb interval (37,566,130–44,870,466)
spanning these seven SNPs in affected dogs showed five

homozygous blocks containing one or two of these seven
significant SNPs, with distances ranging from 45 Kb to 929
Kb (Table 1). Although, assuming recessive inheritance, each
block qualified as a candidate region, we anticipated from
consideration of the genomic structure of the Basenji breed
that the LD block carrying the mutation for the PRA disease
would be larger than 1 Mb [32]. Furthermore, examination
of the 0.9 Mb homozygosity interval on CFA13 (39,172,713–
40,101,896) in the CanFam2 genome assembly did not reveal
any genes appealing as candidates for a retinal degenerative
disorder.
The four SNPs on CFA25 were all within one 2.09 Mb
homozygosity block (46,893,645–48,980,899), in which
all affected dogs were homozygous for one allele for each
SNP, and the three unaffected dogs were homozygous for
the complementary allele. One SNP at position 48,147,815
appeared to break this homozygosity block into two blocks
of 1.25 Mb and 0.83 Mb, but this was considered unreliable
as all genotype calls for this SNP were either heterozygous
or no call (Appendix 3).
Homozygosity analysis: Genotype calls from the affected
dogs only (n=6) were analyzed for homozygosity blocks
greater than 1.0 Mb, excluding sex chromosomes. Five
hundred and thirty-nine such blocks were identified. After
sorting by chromosome and aligning homozygous regions
within each chromosome, five loci were identified where all
1874
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Figure 2. Pedigree of the six
Ba se nji dogs af fe ct ed w it h
progressive retinal atrophy (PRA)
selected as cases for the genomewide association study. Square
symbols=males; Circles=females.
Solid black symbols=affected dogs;
Grey symbols=dogs of unknown
phenotype; half-black/half-gray
symbols=dogs that, assuming autosomal recessive inheritance, are at
least obligate heterozygotes. The
male dog marked with an asterisk
is common to the maternal and
paternal ancestral lines of all six
affected dogs in this pedigree. Not
all ancestors or lines of descent are
shown.

six dogs shared a homozygous segment (Table 2): CFA 6, 17,
21, 25, and 35 with shared block sizes of 2.94, 2.96, 2.73, 1.88,
and 0.78 Mb, respectively. Haplotype analysis confirmed that
all six affected dogs were homozygous for the same haplotype at each region and reduced the sizes of the homozygous
blocks to 2.2, 3.1, 2.84, 2.09, and 0.73 Mb, respectively (Table
2). Two of the three control dogs shared the same genotype as
the affected dogs in all loci except CFA25. None of the three
control dogs carried the risk haplotype on CFA25.

six dogs: two affected Basenji dogs, three non-affected
Basenjis, and one normal Boxer dog.

Evaluation of candidate genes: From association and homozygosity analyses, the association peak on chromosome
25 was considered the best potential candidate region to
investigate further. Within the 2.09 Mb homozygosity block
encompassing all four SNPs with the maximum p value, two
genes were evaluated as positional candidates: KCNJ13 and
SAG. Primer pairs were designed to amplify all exons of both
genes, including flanking sequences from the 5′ untranslated
region (UTR), introns, and 3′ UTR (Appendix 2A, B), and
used to generate amplicons from DNA samples representing

SAG, as identified in the Canfam2 genome sequence
at chr25:47,814,602–47,845,820, comprised 16 exons, 15
of which are coding. Eighteen amplicons were generated
encompassing all exons and their flanking 5′ and 3′ UTRs
and intronic sequence using primers flanking each exon
(Appendix 2A), and sequenced. Ten exonic variations were
identified (Appendix 4B). Two (Nos.1 and 2) were in the 5′
UTR in exons 1 and 2, respectively; five (Nos. 3–7) were
in exonic coding sequence but all represented synonymous

KCNJ13, previously associated with snowflake vitreoretinal degeneration and Leber congenital amaurosis in
humans [30,31], was evaluated with sequence analysis of nine
amplicons (Appendix 2B) encompassing all three exons. Only
one polymorphism was identified (exon 2), and was not in
association with the disease (Appendix 4: A). KCNJ13 was
not further investigated as a candidate.
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Figure 3. Manhattan plot presenting
genome-wide association study
results in Basenji progressive retinal
atrophy (PRA). y-axis=Probability
statistic (–log 10 (P)) for association test analyzed using PLINK.
X-Axis=single nucleotide polymorphisms ordered on chromosomes
(chromosomes 39 and 41 represent
the X-chromosome, and chromosome 40 the Y chromosome).
The highest –log10 (P) values are
observed on CFA4, CFA13, and
CFA25 as denoted by the black
arrows.

third-base codon changes and two (No. 9 and 10) were in the
3′ UTR.
Furthermore, for eight of these ten SAG variations, all
Basenjis (affected and normal dogs) were homozygous for
one allele that differed from the allele in the boxer and the
reference sequence. The two exceptions were variations 8
and 9, which segregated informatively. Since SNP number 9
was located in the 3′ UTR of the gene, it seemed unlikely to
represent a causative mutation.
Variation number 8 (Appendix 4B), however, was a much
more significant tyrosine to cysteine transition mutation

at position CFA25:47,845,680 (c.1216T>C; Figure 4) that
changed the normal stop codon to code for the amino acid
arginine, which would result in a deduced addition of 25
amino acids (p.*405Rext*25) to the normal 405 amino acid
protein (Figure 4), and was thus identified as a strong candidate for the causative mutation.
To further evaluate this variation as the candidate mutation, 80 Basenji dogs were then genotyped with PCR amplification and sequencing of SAG exon 18 (Table 3). Eighteen of
these dogs had been diagnosed as phenotypically normal at an
age considered beyond risk for PRA; 19 had been diagnosed

Table 1. Peak Genome-wide Association R esults.
#

Chromosome

SNP

1

4

Base position

Size (Mb) of homozygous block observed in
affected dogs and location (bp)

BICF2P1179952

14,140,022

Not observed

2

BICF2P1417808

37,566,130

0.16 (37,480,062–37,641,454)

3

BICF2S23534826

38,102,290

4

BICF2P802958

38,149,473

5

13

0.24 (38,057,700–38,300,049)

BICF2G630659956

39,187,805

6

BICF2G630659916

39,220,108

7

BICF2S23222210

42,456,241

0.045 (42,415,530–42,460,613)

8

BICF2P1192547

44,870,466

0.17 (44,818,724–44,987,699)

9

BICF2G630105512

47,523,118

10
11
12

25

BICF2P320510

47,531,764

BICF2P1326525

48,454,294

BICF2P1326531

48,455,885

0.93 (39,172,713–40,101,896)

2.09 (46,893,645–48,980,899)

Genome-wide association analysis of CanineHD Illumina SNP array data for 6 PRA-affected Basenji dogs and 3 controls, identified 12
SNPs sharing the highest -log10P-value of 4.6558. The SNP in CFA4 was not within a homozygous block. Seven SNPs in CFA13 were
within three different homozygous blocks, each smaller than 1 Mb. Four SNPs in CFA25 were within a single 2.09 Mb homozygous
block.
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Table 2. Homozygosity analysis, CanineHD Illumina SNP array data in 9 Basenji dogs, 6 cases and 3 controls.
#

CFA

Start position

End position

Size in Mb

Homozygous block location
(bp) and size (Mb) after haplotype analysis

Inclusion of locus
after comparing to
controls

1.

6

3,018,918

5,962,902

2.94

3,692,623- 5,896,276 (2.2)

No

2.

17

19,570,751

22,531,631

2.96

19,570,699- 22,673,502 (3.1)

No

3.

21

5,144,127

7,870,758

2.73

5,095,371- 7,937,895 (2.84)

No

4.

25

47,030,007

48,906,876

1.88

46,893,645- 48,980,899 (2.09)

Yes

5.

35

14,038,185

14,818,637

0.78

14,091,098- 14,818,637 (0.73)

No

Total

5 Loci

11.29 Mb

Five homozygous blocks were identified with sizes between 0.78 and 2.96 Mb. The homozygous block on CFA25 was exclusively present
in the 6 PRA-affected dogs (cases), all other blocks were observed in both cases and controls.

as cases affected with PRA, and six were “suspicious for
PRA” (i.e., tentatively diagnosed clinically as likely to
develop PRA, based on fundus appearance). Phenotypes for
the remaining 37 dogs were unassigned, usually because the
dogs were too young for a confident diagnosis of PRA when
examined. Among the 18 phenotypically normal Basenjis,
17 genotyped as either homozygous for the wild-type allele
at variation number 8 or heterozygous for the presumptive

mutant allele; the remaining dog (phenotypically normal at
6.4 years of age) was homozygous for the mutant allele. Given
the variation in disease onset in some dogs, this finding
was not unexpected. Of the 19 dogs affected with PRA, 17
genotyped homozygous for the mutation, and two dogs were
homozygous for the wild-type allele. In the PRA-suspicious
group, four dogs were homozygous for the mutant allele, and
two were heterozygous for the mutation. Of the 37 dogs with

Figure 4. Sequence of the 3′ end
of canine S-antigen messenger
ribonucleic acid and the deduced
translated protein. Uppercase plain
letters=coding nucleotide sequence;
lower case letters=3′ untranslated
region (UTR); Uppercase bolded
letters=deduced amino acid translation; Period (.) indicates Stop
codon. Bold underlined lowercase
nucleotides (aataaa)=the polyadenylation signal. The sequence ends
where a poly A tail was observed in
X98460 messenger RNA (mRNA)
deposited in the NCBI database. A:
Sequence from a normal Basenji
dog is presented. The normal stop
codon (TGA) is codon 406. A single
nucleotide polymorphism (SNP)
(r=A/G) is observed in the 3′ UTR
of normal dogs as indicated in bold
italics. B: Sequence from a Basenji
dog affected with progressive
retinal atrophy (PRA) is presented.
The red-boxed nucleotide (C) in panel B is the mutation that alters the normal stop codon (TGA) to code for arginine (R=CGA). Amino
acids in red are the additional ones introduced by the nonstop mutation.
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Table 3. Genotype survey in Basenji dogs.

no phenotypic assignment, 16 were homozygous for the wildtype allele, 19 were heterozygous for the mutation, and two
were homozygous for the mutant allele. An allele-specific
extension test was conducted on 110 dogs from 22 different
breeds not known to segregate this disease, and none were
found to carry this mutation (Appendix 1).
Bronzing phenotype and mutation genotype correlation:
The SAG mutation in human Oguchi disease is also causally associated with a discoloration of the fundus, termed the
Mizuo-Nakamura phenomenon. An altered appearance of the
tapetal fundus, characterized by a golden-brown discoloration
and peripheral mottling, is also seen on ophthalmoscopy in
some Basenji dogs, and termed bronzing. The cases and
controls in the present association study were deliberately
chosen from among dogs free of this bronzing phenotype,
whether affected with PRA or not. To evaluate if this
bronzing phenomenon might represent a canine homolog of
the human Mizuo-Nakamura phenomenon, a set of 17 dogs
diagnosed as exhibiting this bronzing, and 26 dogs free of the
trait, were genotyped for the canine SAG non-stop mutation.
No evidence of correlation between the SAG genotype and the
presence or absence of this bronzing phenotype was observed
(data not shown).
DISCUSSION
The online Mendelian inheritance in the animal database
(OMIA) currently lists 614 traits and disorders in dogs, of
which 238 are Mendelian. For 164 of those, the causative
mutation is known. More pertinently, 24 mutations have
currently been reported in 18 genes as causatively associated
with retinal diseases in at least 58 dog breeds. Approximately
12 genes result in a PRA phenotype while the rest affect other
retinal cells or structures [13]. Progress in understanding
canine population structure, genome history, and the
opportunities presented by breeds as isolate populations has
enhanced research by enabling new approaches for mutation
discovery: from candidate gene approach to linkage studies,
through linkage disequilibrium, and most recently GWAS.
The increasing number of trait-causative gene discoveries in
recent years is testimony to the power of these technologies
and approaches, especially when combined appropriately
with canine population structure.
Important criteria in designing an association study
include accurate phenotypic ascertainment to ensure
that cases and controls are assigned correctly, and that all
affected dogs share the same disease; avoidance of stratification between cases and controls to prevent differences
in population structure between these groups; selection of
cases that are the least related to each other, to reduce the LD

Phenotype

Genotype

Total

T/T

C/T

C/C

Normal

7

10

1

18

PRA affected

2

0

17

19

PRA suspicious

0

2

4

6

Phenotype is unavailable

16

19

2

37

Total

25

31

24

80

Eighty pedigree-registered Basenji dogs were genotyped for a
non-stop SAG mutation (c.1216T>C). One phenotypically normal dog genotyped homozygous for the mutation; 2 dogs diagnosed clinically as “PRA affected” genotyped homozygous
wild-type, and 2 dogs diagnosed clinically as “suspicious of
having PRA” genotyped heterozygous.

interval as much as possible; and analysis of pedigrees for
evidence supporting inheritance IBD. Since within breeds
dogs are relatively genetically homogenous, like isolated
human populations, the number of SNP genotypes sufficient
for association mapping is estimated to be much lower than
in diverse human populations, and the number of cases and
controls could be as low as 20 dogs per group [32]. However,
the number of dogs required for association mapping is
also breed dependent, since variation in genomic structure
is evident between breeds, depending on their origin and
history, with factors such as bottlenecks impacting haplotypes and heterogeneity. The Basenji breed, although one of
the most ancient canine breeds, has low genomic diversity,
heterozygosity, and number of haplotypes [32]. This is not
surprising since nearly all the Basenjis in the Western world
descend from a few dogs originally imported from Africa.
This suggested that even lower numbers of cases and controls
than usual might be sufficient for an association study in the
Basenji compared to other breeds.
In designing the present study, careful selection of cases
and controls that most stringently met the GWAS criteria
listed was more critical than the number of cases and controls
enrolled. In particular, cases were selected that had the most
clear-cut and consistent disease (stage II disease), and from
pedigree analysis demonstrated probable IBD recessive
inheritance; and controls were selected that were free of
retinal disease at an age likely to be beyond the apparent age
of risk (at least 6 years of age) and were appropriately related
to the dogs selected as cases. This reduced the number of
“high confidence dogs” selected to just six affected dogs and
three controls.
GWAS initially identified three potentially significant loci associated with the disease phenotype, on CFA4,
CFA13, and CFA25. Haplotype analysis, assuming recessive
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inheritance, excluded the CFA4 locus. Although homozygosity blocks were observed on CFA13 and CFA25 in affected
dogs, the LD expected from the Basenji breed structure
strongly favored CFA25 over CFA13. The success of association mapping combined with homozygosity analysis to
map the disease to a single locus using fewer than ten dogs
confirms that the minimum number of dogs needed for
GWAS is breed dependent, and can be low in breeds where
LD blocks are large. However, the extensive LD (in this case
2.09 Mb) presents a potentially frustrating tradeoff. If either
no obviously appealing candidate genes had been present
within the homozygosity block, or many were, a much larger
number of affected dogs would have been needed to reduce
the LD, the number of potential causative genes, and the
genomic region to be sequenced and further evaluated.
A parallel approach using homozygosity analysis to
directly identify candidate regions was also undertaken.
This method has successfully mapped autosomal recessive
diseases in humans, especially in consanguineous families.
Examples include mapping of a severe autosomal recessive
RP to subsequently identify a causative mutation in MERTK
[33]; mapping of an autosomal recessive early onset generalized dystonia to subsequently identify a causative mutation
in THAP1 [34]; and homozygosity mapping in one affected
member of a consanguineous family segregating an autosomal
recessive RP to identify three candidate regions, totaling 46
Mb, enabling subsequent identification of the causative mutation in C8orf37 [35]. Because dogs within pedigree-registered
breeds comprise relatively homogenous closed populations,
the dogs would be expected to have multiple blocks of homozygosity throughout their genome. That said, if dogs affected
with an autosomal recessive Mendelian trait are chosen to be
closely related enough to ensure IBD inheritance, but not so
closely related that homozygosity segments are excessively
large or numerous, a homozygosity mapping approach can
be successful. In the present study, homozygosity analysis
of six affected dogs genotypes reduced the candidate region
from the complete genome to just five loci spanning a total
of 11 Mb.
Subsequent candidate gene evaluation of the CFA25
interval identified by association and homozygosity mapping
identified a homozygous non-stop SAG mutation in all six
dogs affected with PRA in the study set. Non-stop mutations are point mutations that convert the stop codon to code
for an amino acid, resulting in a deduced elongation of the
C-terminus of the protein since the translation continues into
the (normal) 3′ UTR. In one human study, such non-stop
mutations represented about 0.2% of the codon-changing
mutations (119 examples in 87 genes) [36]. These mutations
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can potentially affect mRNA fate in terms of stability, localization, translation, and regulation or have ramifications at
the protein level in terms of stability, localization, folding,
regulation, and protein–protein interaction. In the mutant
Basenji SAG sequence, the first alternative in-frame stop
codon is 72 bases after the mutated stop codon and 37 bp
upstream from the polyadenylation signal, suggesting that the
mutated protein, if translated, would be extended by a further
25 amino acids (Figure 4, Figure 5A-C). This appears to be a
long enough abnormally extended sequence to support causal
association with a clinical phenotype [37]. Veske et al. [38]
previously amplified a full-length cDNA SAG from a normal
canine retina. Sequence alignment of this cDNA to the canine
genomic CanFam2.0 and CanFam3.0 sequence assemblies
identifies GT-AG donor-acceptor sites for all introns, and a
stop codon at position 1216–1218 in the last coding sequence.
We amplified full-length canine SAG retinal cDNA that
yielded the same open reading frame as Veske et al. [38] and
no other splice variants (data not shown). Moreover, protein
conservation analysis shows that the stop codon is highly
conserved (Figure 5D), suggesting the significance of termination of the C-tail at this position. Either nonsense-mediated
decay or a protein misfolding response would lead to loss
of SAG function. Alternatively, if the protein is successfully
translated, its function would also likely be impaired.
Computational protein analysis of the deduced protein
(expasy) indicates that the additional 25 amino acids would
change the isoelectric point to 6.78 (from 6.0 in the wild-type)
and would add four positively charged residues, for a total of
56 in the mutant versus 52 in the wild-type. Although the estimated half-life, predicted localization, and instability index
would not change, it is not certain that the mutant protein
would fold correctly. If it does, then the mutant protein’s
ability to bind appropriately to its G-protein-coupled receptor,
rhodopsin, would likely be impaired, and this would likely
lead to the retinal degeneration phenotype. SAG (arrestin) is
critically involved in quenching the photoactivated phosphorylated rhodopsin apoprotein (P-Rh*), a process that involves
conformational changes in rhodopsin and SAG [39,40].
Crystal structure studies have shown that arrestins are elongated two-domain molecules, with their C-tail anchored to
the body of their N-domain by bulky hydrophobic residues,
which stabilizes their basal (inactive) conformation [41-44].
Receptor binding induces the release of the C-tail and movement of the two domains relative to each other [39,40]. If
the mutant SAG protein were produced, an elongation of its
C-tail by 25 amino acids would likely impair its ability to be
anchored in its N-domain and to respond accurately, appropriately and in a timely manner to changes in its receptor.
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Figure 5. Comparative sequence
analysis, 3′ region of canine
S-antigen gene. A: This panel
presents the normal reference
canine genomic sequence, from
the CanFam3 canine sequence
assembly, including the 3’ end of
intron 15, complete exon 16, and 3′
end of S-antigen (SAG). Nucleotides
comprising the 3′ end of intron 15,
and the genomic sequence beyond
the 3′ UTR are in black lowercase.
The splice acceptor site, ag, at the 5′
junction of intron 15 and exon 16 is
highlighted in red and bolded. Blue
uppercase characters comprise SAG
exon 16, the terminal exon, with its
stop codon TGA highlighted in red
and bolded. M=C or A, Y=C or T,
indicate observed canine SNPs.
Blue lowercase is the 3′ untranslated region (UTR); r1 and r2 are
A or G SNPs; boxed in gray is the
deduced stop codon in the affected
Basenji; bold and underlined is
the polyadenylation signal. B: The
corresponding sequence observed
in unaffected Basenji alleles is
presented. C: The corresponding
sequence observed in affected
Basenji dogs is presented, in which
the stop codon is mutated to a CGA,
boxed in red, and the mutation C is
labeled in red. The resulting extension of the open reading frame is indicated with italics, and the new deduced stop codon TAG is highlighted
in red. D: Protein conservation analysis of the amino acids translated from the last exon of SAG in six mammalian species. Colors correspond
to physicochemical properties of the residues: red=small, hydrophobic and/or aromatic; blue=acidic; magenta=basic; green=hydroxyl, sulfhydryl, or amine; black dot=stop codon. Conservation symbols indicate: asterisk (*)=positions that have a single, fully conserved residue;
colon (:)=conservation between groups of strongly similar properties - scoring >0.5 in the Gonnet PAM 250 matrix; period (.)=conservation
between groups of weakly similar properties - scoring=<0.5 in the Gonnet PAM 250 matrix. Modified from multiple sequence alignment
generated by Clustal Omega. Nineteen amino acids and the stop codon are highly conserved among human, mouse, rat, horse, cow, and dog.

Because the SAG gene product serves to turn off activated rhodopsin during the phototransduction cascade, it may
be that the “toxic molecule” in SAG associated retinal disease
is the activated but unquenched opsin apoprotein. This has
similarly been suggested as the pathogenetic mechanism in
the T4R opsin mutant dog [45,46] and the T17M opsin mutant
mouse [47], in both of which light exposure dramatically
accelerates the rate of retinal degeneration. Similarly, in the
retinas of SAG knockout mice, photoreceptors are progressively lost when the mice are maintained in cyclic light,

photoreceptor degeneration was prevented by dark-rearing the
mice, and the degeneration was markedly accelerated when
the mice were exposed to constant light [48]. No evidence of
such light-sensitivity affecting the course of retinal disease
in Basenjis has yet been adduced, but this issue needs to be
further evaluated.
In human populations, SAG mutations have previously been associated with Oguchi disease [10,27,29,49-52]
and RP [10,11,28]. In some families, different individuals
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homozygous for the same mutation can be affected either by
Oguchi disease, RP, or both [10,11]. The exact mechanism for
such a wide range of clinical expression is unknown, although
variation in light exposure has been proposed as a possible
modifying factor, based largely on the studies in mouse
models [48]. We found no significant correlation between
bronzing of the fundus and the SAG nonstop mutation. This
suggests that other environmental or genetic factors likely
are responsible for this bronzing phenomena in the retina
of Basenji dogs and that the bronzing phenomenon does not
constitute a risk factor for a Basenji developing this form of
PRA.
In screening a larger set of 43 ophthalmologically evaluated Basenji dogs in the present study, two dogs diagnosed
clinically as affected with PRA were identified as homozygous for the SAG wild-type allele; another 6.5-year-old dog
diagnosed clinically as nonaffected, and initially considered
to be beyond the risk age, was identified as homozygous for
the SAG mutant allele; and two dogs that had been diagnosed
as “suspicious for PRA” at 8 years of age and older were
genotyped as carriers for the mutation (Table 3). As in other
breeds [14,53,54], it is likely that more than one PRA-causing
mutation is segregating in the Basenji breed, and significant
modifying influences—either genetic or environmental—
also influence the clinical expression of disease caused by
the primary mutation. Human patients with the same SAG
mutation as each other can also present a broad spectrum of
phenotypic expression, and this variation is seen even within
a single family, with one member affected with the Oguchi
phenotype and another with RP [11]. Clinical manifestations
associated with an arrestin 1147delA mutation can range from
Oguchi disease and Oguchi disease with partial chorioretinal
degeneration to RP with or without a golden yellow fundus
reflex [55].
Within the 2.09 Mb LD-homozygous interval identified
as the disease locus, four refseq genes are located (EIF4E2,
SAG, UGT1A6, TRPM8) and more than ten non-refseq genes.
Because the present studies were undertaken in a patient
population for which only phenotypic data and DNA were
available, ongoing and future studies in purpose-bred dogs
will provide tissues, previously and currently unavailable, for
functional, molecular, transcriptomic, proteomic, and cytologic studies to address critical questions that arise from the
present investigations, particularly the effect of the non-stop
mutation on the pathology of the disease, and the involvement of other genes within the LD interval on the course of
the disease. Basenji dogs affected with PRA can thus serve
as a novel large animal model of SAG-associated retinal
degeneration, offering investigational opportunities to better
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understand the primary disease mechanism, explore causes
for the wide variation of disease as observed in humans and
Basenji dogs, investigate the effect of the non-stop mutation
on residual function of the protein, test the potential role
of light-exposure on the phenotype, and evaluate potential
therapeutic approaches.
APPENDIX 1. BREEDS AND NUMBER OF DOGS
PER BREED SCREENED FOR SAG MUTATION.
To access the data, click or select the words “Appendix 1.” A
total of 110 dogs from 22 different breeds were tested for SAG
mutation. None of these dogs carry the mutant allele.
APPENDIX 2. PRIMERS USED TO SCREEN
CANDIDATE GENES WITHIN THE LD INTERVAL
ON CFA25.
To access the data, click or select the words “Appendix 2.”
A. Primer information used for SAG screening. B. Primer
information used for KCNJ13 screening. C. Primer information used for the screening of the non-stop mutation in SAG.
In bold and lower case is the base before the last that was
altered from the database in C1 and C2 forward primers. In
red is the mutated base.
APPENDIX 3. GENOTYPE CALLS FOR THE
SIGNIFICANT LOCUS ON CFA25.
To access the data, click or select the words “Appendix
3.” Allele are represented as A or B. Colored in green are
homozygous genotypes for the A allele; Colored in orange
are homozygous genotypes for the B allele; Colored in yellow
are the heterozygous genotypes AB. NA=call is not available.
SNPs within the SAG gene are marked in red. SNPs with
the highest -log10(P) values are highlighted in purple. The
homozygous block is boxed. The beginning and end of the
homozygous block identified by homozygousity analysis are
bold.
APPENDIX 4. EXONIC POLYMORPHISMS (SNPS)
IDENTIFIED WITHIN 2 GENES (KCNJ13 AND SAG)
EVALUATED AS POSITIONAL CANDIDATES FOR
PROGRESSIVE RETINAL ATROPHY (PRA) IN
BASENJI DOGS.
To access the data, click or select the words “Appendix 4.”
All exons from both genes were amplified and sequenced
from a Boxer, two unaffected Basenjis, one PRA affected
Basenji and its unaffected sibling. A. Only one exonic SNP
was identified in KCNJ13; this was not in association with the
Basenji PRA phenotype. B. Ten exonic SNPs were identified
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in SAG. Two (Nos.1 and 2) were in the 5′ UTR of exons 1 and
2, respectively; 5 (Nos. 3–7) were in exonic coding sequence
but each one was a synonymous third-base codon change;
and two (Nos. Nine and 10) were in the 3′UTR. SNP No.
8 (in red), a T>C transition at position 47,845,680 changes
the normal stop codon to code for arginine, and was thus
identified as a candidate for the causative mutation. In bold
are coding sequence SNPs.
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